UNIQURE NV (QURE) Stock Price & Overview
NASDAQ:QURE • NL0010696654
The current stock price of QURE is 9.04 USD. Today QURE is up by 0.11%. In the past month the price decreased by -67.48%. In the past year, price decreased by -26.08%.
QURE Key Statistics
- Market Cap
- 563.102M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.45
- Dividend Yield
- N/A
QURE Stock Performance
QURE Stock Chart
QURE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to QURE. When comparing the yearly performance of all stocks, QURE is a bad performer in the overall market: 93.03% of all stocks are doing better.
QURE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to QURE. QURE has a bad profitability rating. Also its financial health evaluation is rather negative.
QURE Earnings
On March 2, 2026 QURE reported an EPS of -0.56 and a revenue of 5.57M. The company beat EPS expectations (41.97% surprise) and beat revenue expectations (4.94% surprise).
QURE Forecast & Estimates
22 analysts have analysed QURE and the average price target is 51.51 USD. This implies a price increase of 469.8% is expected in the next year compared to the current price of 9.04.
For the next year, analysts expect an EPS growth of -0.18% and a revenue growth 132.5% for QURE
QURE Groups
Sector & Classification
QURE Financial Highlights
Over the last trailing twelve months QURE reported a non-GAAP Earnings per Share(EPS) of -3.45. The EPS increased by 30.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.47% | ||
| ROE | -102.8% | ||
| Debt/Equity | 2.26 |
QURE Ownership
QURE Latest News, Press Relases and Analysis
QURE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 413.319B | ||
| AMGN | AMGEN INC | 16.83 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.62 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.95 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.86 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.48 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About QURE
Company Profile
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Company Info
UNIQURE NV
Paasheuvelweg 25a
Amsterdam NOORD-HOLLAND 1105 BP NL
CEO: Matthew Kapusta
Employees: 209
Phone: 31202406000
UNIQURE NV / QURE FAQ
Can you describe the business of UNIQURE NV?
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 209 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
What is the current price of QURE stock?
The current stock price of QURE is 9.04 USD. The price increased by 0.11% in the last trading session.
Does QURE stock pay dividends?
QURE does not pay a dividend.
What is the ChartMill technical and fundamental rating of QURE stock?
QURE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is UNIQURE NV worth?
UNIQURE NV (QURE) has a market capitalization of 563.10M USD. This makes QURE a Small Cap stock.
Who owns UNIQURE NV?
You can find the ownership structure of UNIQURE NV (QURE) on the Ownership tab.